Guangzhou Innogen Pharmaceutical Group Co Ltd (HKSE:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
193

Recommended

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.

Harrison Rolfes | 05 June 2026

ASX healthcare giant expected to see uptick in demand from emerging markets.

Lochlan Halloway, CFA | 05 June 2026

Astonishing results have driven this AI stock into significantly overvalued territory.

William Kerwin, CFA | 05 June 2026

Index	Last price	Change	% Change
All Ordinaries	8,855.90	79.60	-0.89%
CAC 40	8,226.41	8.17	0.10%
DAX 40	24,689.66	69.39	-0.28%
Dow JONES (US)	51,066.63	199.85	0.39%
FTSE 100	10,375.23	7.18	0.07%
HKSE	24,657.06	304.89	-1.22%
NASDAQ	26,028.51	319.08	1.24%
Nikkei 225	64,024.60	2,563.52	-3.85%
NZX 50 Index	13,038.24	123.73	-0.94%
S&P 500	7,445.20	61.46	0.83%
S&P/ASX 200	8,625.10	80.00	-0.92%
SSE Composite Index	3,959.34	68.40	-1.70%